Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Cowin Biotech CoSHSE:688426 +2.34%63 Days Payable is 60.85 as of Mar. 2026, which is 6% below its 10-year median of 64.81. GuruFocus rates SHSE:688426 with a GF Score™ of 63/100 and a GF Value™ of ¥29.27 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Jiangsu Cowin Biotech Co ranks worse than 59.4% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688426 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Cowin Biotech Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Jiangsu Cowin Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Jiangsu Cowin Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Cowin Biotech Co (SHSE:688426) has a Days Payable of 60.85 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu Cowin Biotech Co and its competitors. This is near median its historical median of 64.81. Over the past decade, Jiangsu Cowin Biotech Co's Days Payable has ranged from 34.59 to 275.80. According to the industry distribution chart, Jiangsu Cowin Biotech Co ranks #417 out of 702 companies in the Biotechnology industry, placing it in the top 59.4%.
Is Jiangsu Cowin Biotech Co's Days Payable too high?
Jiangsu Cowin Biotech Co's current Days Payable of 60.85 is near median its 10-year median of 64.81. Over the past 10 years, this metric has ranged from a low of 34.59 to a high of 275.80. The Biotechnology industry median Days Payable is 113.10. Jiangsu Cowin Biotech Co's value of 60.85 is 46.2% below this industry median. Based on the distribution chart, Jiangsu Cowin Biotech Co ranks #417 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jiangsu Cowin Biotech Co has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Cowin Biotech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Cowin Biotech Co ranks #417 out of 702 companies for Days Payable. This places Jiangsu Cowin Biotech Co in the lower half of its industry. The industry median Days Payable is 113.10. Jiangsu Cowin Biotech Co's value of 60.85 is 46.2% below this benchmark. Historically, Jiangsu Cowin Biotech Co's own Days Payable has ranged from 34.59 to 275.80 over the past decade. While the company's 10-year median is 64.81 vs. the industry median of 113.10, Jiangsu Cowin Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Cowin Biotech Co's current Days Payable of 60.85 is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu Cowin Biotech Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Cowin Biotech Co's current Days Payable is 60.85, which is near median its own 10-year median of 64.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Cowin Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co (SHSE:688426) is currently considered Possible Value Trap. The stock's GF Value™ is ¥29.27, compared to a current price of ¥15.30 — trading 47.7% below its estimated fair value. The current Days Payable is 60.85, which is near median its 10-year median of 64.81 and 46.2% below the Biotechnology industry median of 113.10. Jiangsu Cowin Biotech Co's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jiangsu Cowin Biotech Co (SHSE:688426), the current Days Payable is 60.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Cowin Biotech Co (SHSE:688426) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co stock appears to be undervalued.
The current stock price of ¥15.30 is trading 47.7% below its estimated GF Value™ of ¥29.27.
GuruFocus considers Jiangsu Cowin Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688426:
Days Payable: 60.85 (near median its 10-year median of 64.81)
GF Value™: ¥29.27 vs. price of ¥15.30 (47.7% below fair value)
Industry Position: 46.2% below the Biotechnology median (#417 of 702)
No single metric tells the full story. See the SHSE:688426 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
63GF Score
Get the complete analysis for SHSE:688426
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688426 has been successfully added to your 
